Healios KK

Healios KK, a small-cap pharmaceutical company, has faced significant challenges, with shares declining notably today and over the past week. Despite a strong one-year return, its long-term outlook is concerning due to negative financial metrics and poor performance over the last five years, raising questions about future growth potential.

Healios KK has seen a notable rise in stock performance, gaining 8.53% on April 1, 2026, and reaching an intraday high of JPY 407.00. Year-to-date, the company has increased by 48.54%, outperforming the Japan Nikkei 225 index, despite facing challenges such as negative EBITDA and low return on equity.

Healios KK, a small-cap pharmaceutical company, saw its stock decline significantly today, reaching an intraday low. While it has outperformed the Nikkei 225 year-to-date, the company faces challenges, including negative return on equity and limited long-term growth prospects, raising concerns about its market position.

Healios KK, a small-cap pharmaceutical company, experienced a significant rise in stock price on March 24, 2026, outperforming the Japan Nikkei 225. Despite recent gains and a positive monthly trend, the company faces long-term challenges, including a substantial decline over five years and concerning financial metrics.

Healios KK, a small-cap pharmaceutical company, saw its shares decline significantly today, marking an 8.06% drop. Despite a year-to-date increase, the stock has underperformed relative to the Japan Nikkei 225. Financial metrics reveal ongoing challenges, including negative return on equity and a low operating profit growth rate.

Healios KK, a small-cap pharmaceutical company, saw its stock decline significantly amid a broader market downturn, despite a strong performance over the past year. The company faces challenges, including negative return on equity and a high debt-to-equity ratio, while remaining categorized as a Hidden Turnaround on MarketsMOJO.

Healios KK, a small-cap pharmaceutical company, saw its stock price decline significantly today, despite a strong performance over the past week and month. The company faces financial challenges, including a negative return on equity and a concerning debt-to-equity ratio, raising questions about its long-term growth prospects.

Healios KK, a small-cap pharmaceutical company, experienced notable trading activity, gaining 14.29% today and reaching an intraday high. Over the past week and month, the stock has shown significant increases, although it faces long-term challenges, including a substantial decline over five years and concerns about financial stability.

Healios KK, a small-cap pharmaceutical company, saw its stock rise significantly on November 13, 2025, despite facing recent declines over the past week and month. However, the company has shown strong annual growth, outperforming the Japan Nikkei 225, while struggling with negative returns on equity and a high debt-to-equity ratio.

Healios KK, a small-cap pharmaceutical company, faced a notable stock decline today, reflecting ongoing challenges. Despite a strong year-to-date performance, the company has struggled with significant decreases in net sales and negative return on equity, raising concerns about its financial stability and long-term growth potential.

Healios KK, a small-cap pharmaceutical company, faced significant stock volatility on October 14, 2025, with an 8.24% decline. Despite a strong year-to-date performance of 164.41%, the company struggles with negative return on equity and declining net sales, raising concerns about its long-term growth potential.

Healios KK, a small-cap pharmaceutical company, saw its stock decline significantly today, reaching an intraday low. Despite a strong performance over the past year, the company faces challenges with negative financial indicators, including a substantial drop in net sales and a concerning return on equity.